Lineage Cell Therapeutics Inc. (LCTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Lineage Cell Therapeutics...

    AMEX: LCTX · Real-Time Price · USD
    1.28
    -0.02 (-1.54%)
    At close: Sep 11, 2025, 3:59 PM

    Lineage Cell Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 9.5M 8.95M 14.7M 3.9M
    Cost of Revenue
    		 334K 671K 728K 1.43M
    Gross Profit
    		 9.16M 8.27M 13.97M 2.47M
    Operating Income
    		 -21.48M -24.73M -22.52M -49.21M
    Interest Income
    		 1.72M 1.63M 829K 2K
    Pretax Income
    		 -18.58M -23.28M -25.81M -43.27M
    Net Income
    		 -18.61M -21.49M -26.35M -43.02M
    Selling & General & Admin
    		 18.17M 17.3M 22.51M 18.21M
    Research & Development
    		 12.47M 15.71M 13.99M 33.91M
    Other Expenses
    		 n/a n/a n/a -445K
    Operating Expenses
    		 30.64M 33.01M 36.49M 51.68M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 30.98M 33.68M 37.22M 53.11M
    Income Tax Expense
    		 27K -1.8M 541K -4.71M
    Shares Outstanding (Basic)
    		 200.19M 172.66M 169.79M 164.5M
    Shares Outstanding (Diluted)
    		 200.19M 172.66M 169.79M 164.5M
    EPS (Basic)
    		 -0.09 -0.12 -0.15 -0.26
    EPS (Diluted)
    		 -0.09 -0.12 -0.15 -0.26
    EBITDA
    		 -20.87M -24.04M -21.79M -48.34M
    EBIT
    		 -21.48M -24.73M -22.52M -49.21M
    Depreciation & Amortization
    		 609K 692K 727K 887K

    Add to Watchlist